Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer

Dr Rugo discusses the second interim analysis of overall survival in the TROPiCS-02 trial, the implications of post-progression treatments after ribociclib and endocrine therapy in the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal starting doses of first-line ribociclib in hormone receptor–positive breast cancer.